IMBRUVICA ® (ibrutinib) in Combination with Rituximab Showed Greater Efficacy Compared to Placebo Plus Rituximab in Patients with Waldenström’s Macroglobulinemia, a Rare and Incurable Form of Non-Hodgkin’s Lymphoma
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Lymphoma | Macroglobulinemia | Pharmaceuticals | Rituxan | Waldenstrom's Macroglobulinemia